UNSPSC 51431804: Azilsartan

This classification denotes an angiotensin ii receptor antagonist with the molecular formula C25H20N4O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F9NUX55P23, chemically known as 2-ethoxy-3-[[4-[2-(5-oxo-2H-1,2,4-oxadiazol-3-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid but generally known as Azilsartan, which bears US NIH Compound Identifier 9825285. European Medicines Agency schedules Azilsartan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB31561.

UNSPSC 51431804 Azilsartan, a Commodity code, covers pharmaceutical products that state and local governments procure for emergency medical services, public health programs, and multistate cooperative purchasing networks. Recent solicitations show purchasing departments, health agencies, and cooperative alliances buying specific medications — including azilsartan and related cardiovascular drugs — as line items within broader pharmaceutical procurement vehicles. The scope spans individual medication units with strict expiration and storage requirements, bulk supplies for emergency response systems, and participation in multistate generic pharmaceutical frameworks. Issuing bodies include city fire-rescue departments, state health and human services commissions, and multistate cooperative purchasing alliances; the City of Tampa and the Minnesota Department of Administration (through MMCAP) appear as active procurement drivers in the recent record.

Activity concentrates in Florida and Minnesota, with Texas HHS Commission participation signaling national interest in pharmacy benefit innovation. Representative opportunities include the City of Tampa's sealed-bid procurement (26P00188, due April 8, 2026) for Advanced Life Support Medications including labetalol, epinephrine, adenosine, and diltiazem for Tampa Fire Rescue, with a $40,000 estimated value and a Small Local Business Enterprise sheltered-market designation offering a 5 percent bid discount; the Minnesota Multistate Cooperative Purchasing Alliance's RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, with pricing-weighted evaluation (75 percent) and mandatory relationships with three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson); and the Texas HHS Commission's Request for Information (HHS0017013, posted April 3, 2026) exploring direct-to-manufacturer prescription capabilities outside traditional pharmacy benefit manager and group purchasing organization channels. Fire-rescue and state health program renewals drive near-term volume; cooperative purchasing agreements represent longer-cycle, multistate demand.